Q2-osavuosiraportti
93 päivää sitten‧29 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
25 625
Myynti
Määrä
55 330
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 651 | - | - | ||
| 149 | - | - | ||
| 1 | - | - | ||
| 850 | - | - | ||
| 1 246 | - | - |
Ylin
1,15VWAP
Alin
1,08VaihtoMäärä
0,6 550 860
VWAP
Ylin
1,15Alin
1,08VaihtoMäärä
0,6 550 860
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenBioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.- ·1 päivä sittenStock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
·2 päivää sittenBioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html
·2 päivää sittenGood, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.
·1 päivä sittenRead the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
·11.11.Any thoughts on the nice rise today?
·3 päivää sitten · MuokattuMust admit I've had enough of this stock which I've held for many years, resulting in a large loss. It should have been sold years ago. They keep spending more money than they have, i.e., the investors' money. Have a quarter left which I'm pulling out now, before that also gets squandered by the company 🤔
·11.11.When will the next dilution come? How long do they really have money to continue? I only have one share left and don't follow much here anymore :D·1 päivä sittenI have permanently said goodbye to the stock today, sold all my shares. It is a company that has diluted its shareholders from day one until now, No progress in the stock, only red in red throughout all the years. 🤔😡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
93 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenBioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.
- ·1 päivä sittenStock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
- ·2 päivää sittenBioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html·2 päivää sittenGood, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.·1 päivä sittenRead the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
- ·11.11.Any thoughts on the nice rise today?·3 päivää sitten · MuokattuMust admit I've had enough of this stock which I've held for many years, resulting in a large loss. It should have been sold years ago. They keep spending more money than they have, i.e., the investors' money. Have a quarter left which I'm pulling out now, before that also gets squandered by the company 🤔
- ·11.11.When will the next dilution come? How long do they really have money to continue? I only have one share left and don't follow much here anymore :D·1 päivä sittenI have permanently said goodbye to the stock today, sold all my shares. It is a company that has diluted its shareholders from day one until now, No progress in the stock, only red in red throughout all the years. 🤔😡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
25 625
Myynti
Määrä
55 330
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 651 | - | - | ||
| 149 | - | - | ||
| 1 | - | - | ||
| 850 | - | - | ||
| 1 246 | - | - |
Ylin
1,15VWAP
Alin
1,08VaihtoMäärä
0,6 550 860
VWAP
Ylin
1,15Alin
1,08VaihtoMäärä
0,6 550 860
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
93 päivää sitten‧29 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 19.11. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. | |
| 2024 Q3-osavuosiraportti | 14.11.2024 |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenBioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.
- ·1 päivä sittenStock exchange announcement yesterday: "Jens Due Olsen, Chairman of the Board of BioPorto, states: “We greatly appreciate the strong support from both existing shareholders and new institutional and private investors, supplemented by strong commitment from BioPorto’s Board of Directors and management. The directed issue provides the financial flexibility needed to advance our strategic priorities, including completing data collection, submitting a pre-submission to the FDA, and initiating the validation study in BioPorto’s US clinical trials, while simultaneously strengthening our commercial platform. In determining the size of this issue, the Board has considered the company’s future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”"
- ·2 päivää sittenBioPorto executes its financing strategy - BioPorto A/S initiates pre-subscribed private placement https://www.globenewswire.com/news-release/2025/11/13/3187745/0/en/BioPorto-Executes-on-its-Financing-Strategy-BioPorto-A-S-initiates-pre-subscribed-private-placement.html·2 päivää sittenGood, so it's out of the system. And hopefully the penultimate emission for BioPorto. They announce that 60-70 mio. needs to be used before expected positive cash flow H2 2027. So an extra 20-30 mio. is needed in the coffers in about 1 year's time.·1 päivä sittenRead the announcement properly now….now note the word “ primarily… “In determining the size of this issuance, the board has taken into account the company's future financing opportunities, primarily in the form of potential divestments of non-strategic assets, supplemented by credit facilities. The decision ensures a balanced and sound financing structure that covers the expected consumption through 2026 and thereby strongly positions the company on the journey towards positive cash flow in the second half of 2027.”
- ·11.11.Any thoughts on the nice rise today?·3 päivää sitten · MuokattuMust admit I've had enough of this stock which I've held for many years, resulting in a large loss. It should have been sold years ago. They keep spending more money than they have, i.e., the investors' money. Have a quarter left which I'm pulling out now, before that also gets squandered by the company 🤔
- ·11.11.When will the next dilution come? How long do they really have money to continue? I only have one share left and don't follow much here anymore :D·1 päivä sittenI have permanently said goodbye to the stock today, sold all my shares. It is a company that has diluted its shareholders from day one until now, No progress in the stock, only red in red throughout all the years. 🤔😡
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
25 625
Myynti
Määrä
55 330
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 651 | - | - | ||
| 149 | - | - | ||
| 1 | - | - | ||
| 850 | - | - | ||
| 1 246 | - | - |
Ylin
1,15VWAP
Alin
1,08VaihtoMäärä
0,6 550 860
VWAP
Ylin
1,15Alin
1,08VaihtoMäärä
0,6 550 860
Välittäjätilasto
Dataa ei löytynyt